166 related articles for article (PubMed ID: 17262238)
1. [Somatostatin analogue treatment in Graves' ophthalmopathy: a case report].
Coloma-González I; Mengual-Verdú E; Domínguez-Escribano JR; Hueso-Abancens JR
Arch Soc Esp Oftalmol; 2007 Jan; 82(1):51-4. PubMed ID: 17262238
[TBL] [Abstract][Full Text] [Related]
2. [Octreotide scintigraphy in thyroid orbitopathy].
Aguirre-Balsalobre F; Mengual-Verdú E; Muñoz-Acosta JM; Martínez-Caballero A; Caballero-Carpena O; Hueso-Abacens JR
Arch Soc Esp Oftalmol; 2007 Mar; 82(3):133-9. PubMed ID: 17357889
[TBL] [Abstract][Full Text] [Related]
3. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today.
Krassas GE; Gogakos A; Boboridis K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():204-9. PubMed ID: 20467364
[TBL] [Abstract][Full Text] [Related]
5. Novel treatment modalities for Graves' orbitopathy.
Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
[TBL] [Abstract][Full Text] [Related]
6. [Somatostatin analogs].
Krysiak R; Okopień B; Herman ZS
Pol Arch Med Wewn; 2006 Oct; 116(4):988-97. PubMed ID: 18416302
[No Abstract] [Full Text] [Related]
7. Currently available somatostatin analogs are not good for Graves' orbitopathy.
Tanda ML; Bartalena L
J Endocrinol Invest; 2006 May; 29(5):389-90. PubMed ID: 16794359
[No Abstract] [Full Text] [Related]
8. Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.
Chang TC; Liao SL
J Endocrinol Invest; 2006 May; 29(5):413-22. PubMed ID: 16794364
[TBL] [Abstract][Full Text] [Related]
9. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.
Cozma I; Zhang L; Uddin J; Lane C; Rees A; Ludgate M
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1630-5. PubMed ID: 17848636
[TBL] [Abstract][Full Text] [Related]
10. Intravenous cyclophosphamide pulse therapy is effective for refractory Graves' ophthalmopathy.
Tanikawa T; Okada Y; Tanaka Y
J UOEH; 2006 Jun; 28(2):185-91. PubMed ID: 16780226
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
Krassas GE
Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
[TBL] [Abstract][Full Text] [Related]
12. [Lanreotide in the treatment of thyroid orbitopathy].
Pilarska K; Kulig G
Przegl Lek; 2004; 61(8):845-7. PubMed ID: 15789913
[TBL] [Abstract][Full Text] [Related]
13. Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.
Su DH; Chang YC; Liao SL; Chang TC
Graefes Arch Clin Exp Ophthalmol; 2005 Mar; 243(3):269-72. PubMed ID: 15452720
[TBL] [Abstract][Full Text] [Related]
14. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
16. Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves' Ophthalmopathy: a case report.
Rau A; Klopfer M; Rommel N; Rau-Fornefeld M; Kolk A
BMC Ophthalmol; 2018 Feb; 18(1):56. PubMed ID: 29482520
[TBL] [Abstract][Full Text] [Related]
17. Latanoprost is effective in reducing high intraocular pressure associated with Graves' ophthalmopathy.
Gumińska M; Kłysik A; Siejka A; Jurowski P
Klin Oczna; 2014; 116(2):89-93. PubMed ID: 25345284
[TBL] [Abstract][Full Text] [Related]
18. Practical Guidelines Management of Graves Ophthalmopathy.
Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
[TBL] [Abstract][Full Text] [Related]
19. Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy.
Kotwal A; Stan M
Horm Metab Res; 2018 Dec; 50(12):871-886. PubMed ID: 30286486
[TBL] [Abstract][Full Text] [Related]
20. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
